22/11/2022 - 17:08

Radiopharm inks ANSTO deal for cancer-fighting agent

22/11/2022 - 17:08


Save articles for future reference.

Melbourne-based Radiopharm Theranostics has reached an agreement with Australia's Nuclear Science and Technology Organisation for the supply of a vital ingredient required for its fight against cancer. The ingredient is a short-lived radioactive isotope called non-carrier-added lutetium-177, or Lu-177, that has promising properties for treating certain cancers. Lu-177 will be used in an upcoming trial of patients with lung cancer.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options